Overview
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Eligibility
Inclusion Criteria:
- Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months
- Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening
- Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m²)
- Participants are insulin naïve or have been without insulin treatment for at least 3 months prior to screening
Exclusion Criteria:
- Have had a severe hypoglycemia in the past 6 months
- Have a history of renal impairment
- Have had a blood transfusion or severe blood loss within last 90 days
- Have had a significant weight gain or loss of approximately 6% or more within 3 months prior to screening.
- Have a history of an active or untreated malignancy
- Are receiving or received systemic glucocorticoid therapy
- Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product